Connor Kevin T, Aylward Lesa L
Geomatrix, Inc., Folsom, California, USA.
J Toxicol Environ Health B Crit Rev. 2006 Mar-Apr;9(2):147-71. doi: 10.1080/15287390500196487.
The aryl hydrocarbon receptor (AhR) mediates nearly all studied adverse effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and many related compounds. Binding of TCDD or related ligands to AhR is the key initiating event in downstream biochemical responses. The binding affinity of AhR for TCDD is specific to species and strain, and studies of human AhR demonstrate binding affinities approximately an order of magnitude or more lower than those observed in the most sensitive laboratory strains and species. Molecular genetic studies confirmed that human AhR shares key mutations with the DBA mouse strain that result in an "impaired" AhR (with respect to TCDD binding and responsiveness). Despite a number of polymorphisms in human AhR, the key "DBA-type" mutations appear to be a constant feature of the human AhR, and no polymorphisms have been identified that compensate for the impaired binding function conferred by these mutations. Consistent with the impaired binding status of the human AhR, human cells have consistently required approximately 10-fold higher concentrations of TCDD in vitro than rodent cells to respond with enzyme induction. Recent studies of in vivo enzyme induction-related endpoints in human populations with moderately and highly increased TCDD body burdens detected no relationship between these endpoints and TCDD body burdens at body-burden levels up to 250 ng TEQ/kg body weight, or approximately 25 times above the upper range of current general population background body burdens, while marked elevations in enzyme activity were observed in persons with body burdens above 750 ng TEQ/kg. In contrast, the more sensitive laboratory rodent strains and species exposed to TCDD exhibit significant enzyme induction at body burdens below 50 ng/kg. These interspecies data on the most sensitive and best understood response to binding of TCDD and related compounds to the AhR are consistent with the binding affinity and molecular structure data and support the hypothesis that the human AhR is less functional than the AhR of the more sensitive laboratory animals at a molecular level. Quantitative risk assessments involving interspecies extrapolation from sensitive laboratory species and strains should take these fundamental differences into account when margins of exposure and safety factors are considered.
芳烃受体(AhR)介导了几乎所有已研究的2,3,7,8 - 四氯二苯并 - p - 二恶英(TCDD)及许多相关化合物的不良反应。TCDD或相关配体与AhR的结合是下游生化反应中的关键起始事件。AhR对TCDD的结合亲和力因物种和品系而异,对人类AhR的研究表明,其结合亲和力比在最敏感的实验室品系和物种中观察到的低约一个数量级或更多。分子遗传学研究证实,人类AhR与DBA小鼠品系存在关键突变,导致AhR“功能受损”(就TCDD结合和反应性而言)。尽管人类AhR存在许多多态性,但关键的“DBA型”突变似乎是人类AhR的一个恒定特征,尚未发现能补偿这些突变所导致的结合功能受损的多态性。与人类AhR结合状态受损一致,在体外,人类细胞对酶诱导反应所需的TCDD浓度一直比啮齿动物细胞高约10倍。最近对体内TCDD体内负荷中度和高度增加的人群进行的与酶诱导相关终点的研究发现,在体内负荷高达250 ng TEQ/kg体重(约为当前一般人群背景体内负荷上限的25倍)时,这些终点与TCDD体内负荷之间没有关系,而体内负荷高于750 ng TEQ/kg的人则观察到酶活性显著升高。相比之下,接触TCDD的更敏感的实验室啮齿动物品系和物种在体内负荷低于50 ng/kg时就表现出显著的酶诱导。这些关于TCDD及相关化合物与AhR结合的最敏感且理解最透彻的反应的种间数据与结合亲和力和分子结构数据一致,并支持这样的假设:在分子水平上,人类AhR的功能比更敏感的实验动物的AhR要弱。在考虑暴露余量和安全系数时,涉及从敏感实验室物种和品系进行种间外推的定量风险评估应考虑这些基本差异。